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Summary
Background.— Cardiovascular disease is the primary cause of mortality and morbidity among
patients with chronic kidney disease.
Aims.— To investigate whether echocardiography can predict the occurrence of major cardio-
vascular events in patients with severe chronic kidney disease.
Patients.— Patients with stable stage 4 chronic kidney disease (estimated glomerular ﬁltra-
tion rate 15—29mL/min/1.73m2) and followed in the nephrology department were included.
Clinical, biological, electrocardiographic and echocardiographic data were recorded. Endpoint
was deﬁned as fatal or non-fatal cardiovascular event (acute coronary syndrome, acute heart
failure, stroke, sustained ventricular arrhythmias, arterial thrombotic events and death).
Results.— We included 71 patients (46 men); mean age 72± 14 years. Mean glomerular ﬁltration
rate was 21.9± 4.8mL/min/1.73m2. Over a mean follow-up of 258± 30 days, 18 (25%) patients
reached endpoint (death in 7/18). Male sex, blood urea, atrial ﬁbrillation, Sokolow index, left
atrial size, pulmonary arterial pressure, indexed left ventricular mass and protodiastolic peak
velocity of transmitral Doppler ﬂow were signiﬁcantly higher whereas left ventricular ejection
Abbreviations: AF, atrial ﬁbrillation; CI, conﬁdence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; LVEF, left ven-
ricular ejection fraction; LVH, left ventricular hypertrophy; MACE, major acute cardiac and vascular events; MDRD, Modiﬁcation of Diet in
enal Disease; OR, odds ratio; ULN, upper limit of normal.
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fraction was signiﬁcantly lower in these patients. By multivariable analysis, blood urea and
left ventricular ejection fraction remained predictive of major cardiovascular event with odds
ratios of 1.10 (95% conﬁdence interval 1.02—1.18) and 0.93 (95% conﬁdence interval 0.89—0.97),
respectively. The negative predictive value was 95% when left ventricular ejection fraction
was > 50% with blood urea < 15mmol/L.
Conclusion.— Patients with stage 4 chronic kidney disease are at high risk of major cardio-
vascular events and death. Echocardiographic evaluation is effective in identifying patients at
highest risk of adverse cardiac events.
© 2013 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Les maladies cardiovasculaires sont la première cause de morbimortalité en cas
d’insufﬁsance rénale chronique.
Objectif.— Déterminer si l’échographie pouvait prédire la survenue d’événements indésirables
cardiovasculaires majeurs en cas d’insufﬁsance rénale chronique sévère.
Patients.— Les patients avec insufﬁsance rénale chronique sévère (stade 4, débit de ﬁltra-
tion glomérulaire entre 15 et 29mL/min/1,73m2) stable suivis en néphrologie ont été inclus.
Les données cliniques, biologiques, électrocardiographiques et échographiques ont été enreg-
istrées. Le critère d’évaluation a été déﬁni par la survenue d’événements cardiovasculaires
mortels ou non (syndrome coronarien aigu, insufﬁsance cardiaque aiguë, accident vasculaire
cérébral, arythmie ventriculaire soutenue, événements thrombotiques artériels et décès).
Résultats.— Nous avons inclus 71 patients (46 hommes), d’âge moyen 72± 14 ans. Le débit de
ﬁltration glomérulaire moyen était de 21,9± 4,8mL/min/1,73m2. Au cours d’un suivi moyen de
258± 30 jours, 18 patients (25 %) ont atteint le critère d’évaluation (dont sept décès). Le sexe
masculin, l’urémie, la ﬁbrillation atriale, l’indice de Sokolow, la taille de l’oreillette gauche, la
pression artérielle pulmonaire, la masse ventriculaire gauche indexée et le pic protodiastolique
du ﬂux doppler transmitral étaient signiﬁcativement plus élevés alors que la fraction d’éjection
ventriculaire gauche signiﬁcativement plus faible chez ces patients. En analyse multivariée,
l’urémie et la fraction d’éjection ventriculaire gauche restaient prédictives d’évènement (OR
1,10 (IC 95% [1,02, 1,18]) et 0,93 IC 95% [0,89, 0,97], respectivement). La valeur prédictive
négative était de 95% lorsque la fraction d’éjection ventriculaire gauche était supérieure à 50%
avec une urémie inférieure à 15mmol/L.
Conclusion.— La morbimortalité cardiovasculaire est élevée en cas d’insufﬁsance rénale
chronique sévère. L’évaluation échocardiographique est efﬁcace pour identiﬁer les patients
à haut risque.
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Background
A strong association exists between chronic kidney disease
(CKD) and cardiovascular disease (CVD), with an increase
in CVD observed with declining glomerular ﬁltration rate
[1—5]. Indeed, CVD is the main cause of morbidity and
mortality in CKD patients. In a study conducted by Go
et al. [2], with more than one million patients classiﬁed
into subgroups according to CKD stage, annual mortal-
ity and cardiovascular morbidity were 11.4% and 21.8%,
respectively, in stage 4 patients. Cardiovascular risk is, how-
ever, difﬁcult to assess in patients with stage 4 or stage
5 CKD, and risk scores, such as those derived from the
Framingham study, are not accurate in the CKD population
[6].
In patients undergoing dialysis, the value of echocardiog-
raphy to predict cardiovascular events and death has been
reported [7—11]. However, data are lacking from patients
with stage 4 CKD to help identify those at higher risk of
cardiovascular morbidity [12,13]. Using the modiﬁcation
of diet in renal disease (MDRD) formula [14], 0.5% of the
a
d
es droits réservés.
dult participants in the NHANES 1999—2006 cohort had
n estimated glomerular ﬁltration rate < 30mL/min/1.73m2
15]. Few studies have been conducted in these patients
mainly evaluations of subgroups. In addition, random-
zed clinical trials usually exclude patients with severe
KD [16,17]. Unlike patients undergoing dialysis, stage
CKD patients are not generally considered as a spe-
iﬁc population in the cardiology setting and no speciﬁc
chocardiographic data from these patients have been
eported [18]. However, earlier detection of patients
t high risk of cardiovascular complications could help
hysicians to adapt therapy and follow-up accordingly,
hereby potentially delaying the occurrence of adverse
ardiac events or the initiation of renal replacement ther-
py.
The aim of this prospective cohort study was to iden-
ify echocardiographic variables that may predict cardiac
nd vascular complications in patients with stage 4 CKD
nd to describe cardiovascular status, echocardiographic
ata and occurrence of cardiac and vascular adverse
vents.
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atients
nclusion criteria and study population
n our centre, patients with stable stage 4 CKD are
een in consultation every 3months for regular follow-
p. All prospective patients attending these consultations
ver a period of 5months with stable stage 4 CKD and
n estimated glomerular ﬁltration rate between 15 and
0mL/min/1.73m2 according to the MDRD formula were
onsidered eligible for inclusion. Patients were included
uring their consultation if they gave informed consent.
ata were collected during standard care. Exclusion criteria
ere as follows: acute renal failure with serum creatinine
ncrease of 50% from baseline level in the 3 previous months;
KD diagnosed < 3 months previously; and history of trans-
lantation.
ata collection
ardiovascular history, traditional risk factors for CVD
hypertension, diabetes mellitus, current smoking, hyper-
ipidaemia, being overweight and family history of vascular
isease), the cause of nephropathy and body surface area
ere recorded. In all patients, heart rate and arterial blood
ressure were measured and a 12-lead electrocardiogram
as performed at inclusion.
Transthoracic echocardiography was performed in all par-
icipants, using ACUSON SEQUOIA C256 equipment (Siemens,
unich, Germany) with data obtained in digital format
nd stored for off-line analysis. Two independent opera-
ors interpreted the echocardiography blind with respect to
linical data, according to the American Society of Echocar-
iography recommendations [19], with an average of at least
hree successive measurements (ﬁve if atrial ﬁbrillation
AF] was present). Left ventricular ejection fraction (LVEF)
Simpson’s biplane method), left ventricular mass (cubes
ethod according to American Society of Echocardiography
onvention [20]), left atrium surface area (four-chamber
lanimetry) and pulmonary arterial pressures (derived from
ricuspid and/or pulmonary regurgitation ﬂow) were mea-
ured. Right atrial pressure was estimated by inferior vena
ava diameter and the presence of inspiratory collapse.
nferior vena cava diameter < 2 cm with collapse > 50% dur-
ng inspiration and > 2 cm with collapse < 50% suggested right
trial pressures of 5 and 15mmHg, respectively; intermedi-
te cases suggested a right atrial pressure of 10mmHg. Left
entricular ﬁlling pattern was also collected with transmi-
ral Doppler ﬂow analysis and the measurements of E mitral
rotodiastolic peak velocity, E mitral deceleration time, A
itral end-diastolic peak velocity, A mitral duration, isovol-
metric relaxation time and Doppler tissue imaging on the
ateral side of mitral annulus (early peak velocity). Valvular
iseases were quantiﬁed using the reference methods. Left
entricular mass and aortic valve area were indexed to body
urface area.
LVEF < 50%, indexed left ventricular mass > 95 g/m2
or women and > 115 g/m2 for men, left atrial sur-
ace area > 20 cm2 and systolic pulmonary artery pres-
ure > 40mmHg were considered abnormal. Biological varia-
les were also recorded (serum creatinine, blood urea,
alcium, phosphate, protein, albumin, haemoglobin, intact
(
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arathyroid hormone, glycated haemoglobin, C-reactive
rotein and 24-hour proteinuria).
During the follow-up period, all-cause death and car-
iovascular death were recorded. A composite endpoint of
ajor acute cardiac and vascular events (MACE) was deﬁned
s cardiovascular death, non-fatal cardiovascular events,
cute coronary syndromes (with or without ST-segment ele-
ation), ischaemic stroke, acute arterial ischaemia, acute
eart failure or sustained ventricular arrhythmias. In addi-
ion, cardiovascular and all-cause admissions, need for
ialysis, kidney transplant and death were recorded.
The study was designed to follow patients up to 1 year
fter inclusion.
tatistical analysis
uantitative data are presented as mean± standard devi-
tion and qualitative data as number and percentage.
vent-free survival analysis was performed using Kaplan-
eier survival analysis and compared using the log-rank
est. Variables that differed signiﬁcantly between groups
y univariate analysis were included in the multivariable
nalysis, using an ascending stepwise Cox proportional
azards model. We planned to perform the analysis in
wo stages, due to the small number of expected events.
irstly, echocardiographic and non-echocardiographic varia-
les would be analysed separately and the independent
ariables would subsequently be included in the ﬁnal mul-
ivariable analysis combining both echocardiographic and
on-echocardiographic variables. A post hoc analysis of the
redictive value of the combination of independent predic-
ors using established cut-off values was also performed (50%
or LVEF [21] and 2× upper limit of normal [ULN] for urea).
Kaplan-Meier curve was drawn to visualize the progno-
tic value of independent variables signiﬁcantly associated
ith MACE occurrence and of their combination. All analy-
es were performed using SPSS 19 software (IBM, SPSS Inc.
hicago, IL, USA) and for all tests a P value < 0.05 was con-
idered signiﬁcant.
esults
tudy population and MACE
e prospectively screened 78 patients, of whom 71 were
ncluded (46 men and 25 women). Six patients did not give
onsent to participate and one was excluded after echocar-
iography, because of severe aortic valve stenosis requiring
urgery. All but one of the 71 included patients were white,
ean age was 72± 14 years (range 27—95) and 10 patients
ad an arteriovenous ﬁstula.
The baseline characteristics of the study population are
isplayed in Table 1. Only four patients had no risk factors,
hile 15, 22, 15 and 15 patients had one, two, three and four
r more risk factors, respectively. Thirty-one patients had
revious atheromatous disease with a history of at least one
f the following: acute coronary syndrome (n = 15), stroke
n = 9), peripheral arteriopathy (n = 16) and renal artery
tenosis (n = 3). The primary causes of CKD were nephroscle-
osis (41%), diabetic nephropathy (31%), tubulointerstitial
ephritis (10%), chronic glomerulonephritis (8%) and other
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Table 1 Baseline characteristics of the study population.
All (n = 71) Event-free (n = 53) Event (n = 18) P
Men 46 (65) 30 (57) 16 (89) 0.01
Age (years) 72± 14 70.7± 14.5 76± 11.5 0.17
Cardiovascular history
Acute heart failure 14 (20) 7 (13) 7 (39) 0.02
Atheromatous disease 31 (44) 20 (38) 11 (61) 0.06
Cardiovascular risk factors
Hypertension 58 (82) 41 (77) 17 (94) 0.12
Diabetes mellitus 25 (35) 18 (34) 7 (39) 0.79
Dyslipidaemia 30 (42) 24 (45) 6 (33) 0.71
BMI > 25 kg/m2 40 (56) 31 (58) 9 (50) 0.44
Smoking (current/stopped < 3 years) 10 (14) 8 (15) 2 (11) 0.29
Family history of early vascular disease 6 (9) 4 (8) 2 (11) 0.49
Haemodynamic variables
Systolic blood pressure (mmHg) 139± 19 140± 17 137± 22 0.24
Diastolic blood pressure (mmHg) 74± 9 74± 10 72± 7 0.28
Heart rate (beat/min) 69± 12 70± 12 68± 10 0.81
Medical therapy
ACEI or ARB 55 (78) 40 (76) 15 (83) 0.44
Antiplatelet agent 29 (41) 18 (34) 11 (61) 0.11
Statins 17 (24) 11 (21) 6 (33) 0.54
Diuretic 50 (70) 34 (64) 16 (89) 0.002
Beta-blocker 29 (41) 17 (32) 11 (61) 0.049
Biological variables
Creatinine (mol/L) 281± 122 276± 127 295± 107 0.58
eGFR (MDRDmL/min/1.73m2) 21.9± 4.8 22.4± 4.5 20.5± 5.2 0.38
Blood urea (mmol/L) 18.7± 7.0 16.9± 6.1 23.4± 7.2 0.001
Blood urea/creatinine 69± 19 65± 18 81± 18 0.001
Proteinuria (g/24 h) 1.2± 1.6 1.1± 1.4 1.4± 2.1 0.37
Albumin (g/L) 40± 5 40± 24 38± 4 0.13
Calcium (mmol/L) 2.31± 0.16 2.33± 0.15 2.27± 0.17 0.21
Phosphate (mmol/L) 1.34± 0.31 1.32± 0.30 1.40± 0.32 0.33
iPTH (pg/mL) 200± 236 181± 171 234± 326 0.53
HbA1c (%) 6.5± 1.5 6.20± 1.52 6.65± 1.20 0.40
Haemoglobin (g/L) 120 ±12 121± 12 118± 14 0.48
CRP > 3mg/L 34 (48) 17 (32) 6 (33) 0.25
Atrial ﬁbrillation 10 (14) 2 (4) 8 (44) < 0.001
Sokolow index (mm) 20± 7 19± 7 25± 9 0.009
Data are presented as mean± standard deviation or number (%). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-
receptor blocker; BMI: body mass index; CRP: C-reactive protein; eGFR: estimated glomerular ﬁltration rate; HbA1c: glycated
haemoglobin; iPTH: intact parathyroid hormone; MDRD: modiﬁcation of diet in renal disease.
All clinical and electrocardiographic variables were available for each patient. All biological variables were available, except for HbA1c,
which was available only for the 25 diabetic patients (no diabetes was diagnosed during study), and iPTH (50 patients).
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ccauses (10%). Renal biopsy was performed in 14 patients to
conﬁrm the type of nephropathy. Permanent AF was present
in 10 patients (14%).
The echocardiographic ﬁndings are presented in Table 2.
LVEF was < 50% in 10 patients (14%). Left ventricular hyper-
trophy (LVH), high left atrial surface area and elevated
systolic pulmonary artery pressure were observed in 70%,
41% and 13% of patients, respectively. Finally, 26% of the
population had a signiﬁcantly reduced aortic valve area
(< 1 cm2/m2).
f
t
eDuring a mean follow-up of 258± 30 days, 18 patients
25%) reached the composite endpoint, 7 (10%) of whom
ied. All deaths were from cardiac or vascular causes (acute
eart failure [n = 3], mesenteric ischaemia [n = 3] and ven-
ricular ﬁbrillation [n = 1]). Fifty-one hospital admissions
ere documented in 32 patients, of which 57% were for
ardiovascular causes. Nine patients began dialysis during
ollow-up (of whom two died during follow-up, two were
ransplanted and ﬁve were still undergoing dialysis at the
nd of follow-up). One patient underwent transplantation
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Table 2 Echocardiographic characteristics of the study population.
All (n = 71) Event-free (n = 53) Event (n = 18) P
Left ventricular ejection fraction (%) 62 ± 14 66 ± 11 52 ± 16 0.001
Indexed left ventricular mass (g/m2) 133 ± 45 125 ± 43 158 ± 41 0.01
Left atrial surface area (cm2) 19.2 ± 7.3 17.8 ± 5.6 23.2 ± 10.1 0.01
Aortic valve surface area (cm2/m2) 1.3 ± 0.4 1.3 ± 0.4 1.2 ± 0.4 0.16
E mitral wave maximum velocity (cm/s) 77 ± 27 73 ± 23 90 ± 35 0.02
E mitral wave deceleration time (ms) 231 ± 84 235 ± 76 219 ± 105 0.52
Mitral E/A 0.91 ± 0.51 0.85 ± 0.35 1.15 ± 0.96 0.08
E/Ea 6.6 ± 2.4 6.4 ± 2.3 7.3 ± 2.7 0.18
IVRT (ms) 120 ± 29 120 ± 24 122 ± 40 NS
Systolic pulmonary artery pressure (mmHg) 34 ± 10 32 ± 6 39 ± 14 0.02
Data are presented as mean± standard deviation. Ea: early peak velocity; IVRT: isovolumetric relaxation time; NS: not signiﬁcant.
Left ventricular mass was available for 68 patients (long axis parasternal view unusable in three patients). Left ventricular ejection
fraction, left atrial surface area and data from transmitral ﬂow were measurable in 69 patients. E/A ratio was not available in 11
patients (atrial ﬁbrillation in all but one). Systolic pulmonary artery pressure was measured in 58 patients.
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eefore dialysis could be initiated. Follow-up data and details
f MACE are shown in Table 3.
redictors of MACE
he comparison between patients who reached the com-
osite endpoint and those who did not is presented in
ables 1 and 2.
By univariate analysis, there was no difference in age,
istory of atheromatous disease, traditional cardiovascular
isk factors, causes of nephropathy, heart rate and blood
ressure between the two groups. Patients who experienced
ACE more often presented a history of acute heart failure
P = 0.02) or diuretic treatment (P < 0.05) and had a higher
lood urea concentration (P < 0.01). The dose of diuretics
as higher in patients with MACE (93± 84mg vs. 31± 48mg
f furosemide; P < 0.001). We also noted a relation
etween blood urea and diuretic doses (24.8± 8.1mmol/L
or furosemide doses > 60mg vs. 18.1± 5.7mmol/L for
urosemide doses < 60mg [P = 0.002] vs. 15.7± 5.7mmol/L if
o diuretic was prescribed [P < 0.0001]). On electrocardio-
raphy and echocardiography, abnormal ﬁndings were more
requent in MACE patients: AF (44% vs. 4%), LVH (Sokolow
Table 3 Events during follow-up.
Events n (%)
All-cause deaths 7 (10)
Cardiovascular deaths 7 (10)
Cardiac and vascular events 18 (25)
Acute coronary syndromes 3 (4)
Ischaemic stroke 1 (1)
Acute mesenteric or peripheral
artery ischaemia
5 (6)
Acute heart failure 12 (17)
Sustained ventricular arrhythmias 1 (1)
All-cause hospitalizations 32 (45)
End-stage renal disease 9 (13)
Pre-emptive kidney transplantation 1 (1)
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fndex or left ventricular mass), increased left atrial surface
rea, protodiastolic transmitral ﬂow peak, pulmonary artery
ressure and decreased LVEF. Beta-blocker use was higher in
he MACE group. Other medical therapy and biological and
chocardiographic variables were not signiﬁcantly different.
Among the 10 patients with AF, eight reached the com-
osite endpoint (80%) compared with only 10 of the 61 (16%)
atients in sinus rhythm (P < 0.01).
By multivariable analysis of non-echocardiographic data,
lood urea and AF were signiﬁcantly associated with MACE,
ith an odds ratio (OR) of 1.13 (95% conﬁdence interval [CI]
.04—1.22) for an increase of 1mmol/L in blood urea and an
R of 5.40 (95% CI 1.78—16.4) for AF.
By multivariable analysis of echocardiographic varia-
les, LVEF with an OR of 0.95 (95% CI 0.91—0.99) and
eft atrial area with an OR 1.1 (95% CI 1.02—1.17) were
ound to be independently associated with cardiovascu-
ar events, an increase in LVEF having a protective effect.
n the ﬁnal multivariable analysis, which included both
chographic and non-echographic variables signiﬁcantly
ssociated with MACE by univariate analysis, LVEF was
he only echocardiographic factor independently associated
ith MACE (OR 0.93, 95% CI 0.89—0.97; P < 0.001); among
on-echocardiographic variables, only blood urea was sig-
iﬁcantly associated with MACE (OR 1.10, 95% CI 1.02—1.18;
= 0.002).
In a post hoc analysis, when we set cut-off values for
VEF at 50% and blood urea at 15mmol/L (corresponding
o 2×ULN), we found signiﬁcant differences in the rate of
ACE occurrence according to whether 0, 1 or 2 values were
bnormal (Fig. 1). The association of LVEF > 50% and blood
rea < 15mmol/L had a negative predictive value of 95% for
ACE occurrence, with a positive predictive value of 67% if
oth were abnormal (nine patients, of whom six presented
ith MACE).iscussion
o the best of our knowledge, this is the ﬁrst study to
ocus exclusively on patients with stage 4 CKD, assessing
Echo to predict CV events in CKD
Figure 1. Kaplan-Meier curves representing cardiac and vascu-
lar event-free survival. LVEF: left ventricular ejection fraction.
P < 0.01 by the log-rank test. LVEF > 50% and blood urea < 15mmol/L
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tor for CVD mortality in end-stage renal disease patients.(n = 19); LVEF≤ 50% OR blood urea≥ 15mmol/L (not both) (n = 36);
LVEF≤ 50% and blood urea≥ 15mmol/L (n = 9).
both echocardiographic and non-echocardiographic predic-
tors of MACE. Patients were selected according to estimated
glomerular ﬁltration rate, regardless of the origin of their
nephropathy, clinical history and risk factors for CVD.
Ninety-one percent of eligible stage 4 CKD patients were
included and none was lost to follow-up. In contrast with
other epidemiological studies [22], our population was
predominantly male. However, sex was signiﬁcantly (not
independently) associated with MACE.
The prevalences of atheromatous disease and CVD risk
factors were high in our study population, as reported in
larger epidemiological studies [2,23,24], but these factors
were also not shown to be associated with MACE.
We observed a high mortality rate; deaths were mostly
related to cardiovascular causes. The occurrence of MACE,
mainly acute heart failure, was frequent and was the leading
cause of hospitalizations. These results are consistent with
other epidemiological investigations [1,2,4,25]. Go et al. [2]
found an annual mortality rate of 11.4%, with a cardiovascu-
lar event rate of 21.8% per year among stage 4 CKD patients.
Indeed, CKD is known to be an independent risk factor for
death and MACE [2,3,5,26,27].
Keith et al. found that 46% of a cohort monitored for
5.5 years died from CVD before reaching dialysis, while 20%
needed dialysis or were transplanted by the end of the
study [25]. Despite a shorter follow-up period in our study,
MACE occurrence was more frequent than the need for renal
replacement therapy.
Our study focused on echocardiographic evaluation. Few
patients had systolic dysfunction. However, a lower LVEF
was signiﬁcantly associated with MACE occurrence and an
increase of 1% in LVEF was associated with a 7% decrease in
the risk of MACE. This association was independent of other
I
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ariables, including left ventricular mass and left atrial size.
hese patients should beneﬁt from the speciﬁc treatment
ecommended for patients with congestive cardiac failure
nd altered LVEF (namely angiotensin-converting enzyme
nhibitors and beta-blockers), although their efﬁcacy is
ess well established in severe CKD patients [16]. These
esults explain (in addition to using for AF rate control) the
ssociation of beta-blocker use with MACE (not conﬁrmed
n multivariable analysis). Among patients with LVEF < 50%
n = 10), ﬁve had previous documented coronary artery dis-
ase, two had normal coronary angiography and two had
egative non-invasive evaluation of ischaemic risk. Low LVEF
as previously shown to be an independent predictor of car-
iovascular morbidity andmortality in asymptomatic dialysis
atients [11] and of cardiovascular death in patients starting
aemodialysis [9].
Congestive heart failure with preserved LVEF was prob-
bly due to diastolic dysfunction. Echocardiographic data
avour this mechanism, as we found a signiﬁcant association
etween several echocardiographic variables and MACE (left
entricular mass, left atrial size, systolic pulmonary arterial
ressure and E mitral wave), all of which are altered in dia-
tolic dysfunction [28]. Hayashi et al. showed that diastolic
ysfunction is accentuated in patients with severe CKD and
hat echocardiography is useful in identifying it [29].
Left atrial size has been shown to be independently asso-
iated with cardiovascular mortality, regardless of whether
atients required dialysis or had normal kidney func-
ion [30]. Moreover, left atrial dilatation promotes AF,
known risk factor for cardiovascular events in renal
mpairment [31,32] and, consequently, arterial thromboem-
olic complications. In our study, AF was signiﬁcantly and
ndependently associated with MACE occurrence by multi-
ariable analysis of non-echocardiographic variables. AF has
reviously been identiﬁed as a risk factor for cardiovascular
ortality among dialysis patients [31,32], mainly through
he occurrence of fatal stroke, contrary to our patients in
hom acute heart failure was more frequent. Indeed, in
ur ﬁnal multivariable analysis, AF was not shown to be sig-
iﬁcantly related to MACE occurrence, mainly because, in
ur population, it was strongly associated with low ejection
raction and both are responsible for heart failure, which
as the main cause of MACE. AF induces acute heart fail-
re by decreasing systolic ejection volume (by loss of atrial
ystole and myocardial remodelling). Consequently, AF and
ecreased LVEF both contribute to MACE. Moreover, AF is fre-
uently observed in diastolic dysfunction [28] and all these
lements serve to underline the importance of diastolic dys-
unction in these patients.
LVH was the most frequent abnormality observed on our
chocardiographic data, as previously reported in many pub-
ications, ranging from 45% observed by Levin et al. among
atients with creatinine clearance < 25mL/min [33], to 66%
n a report by Hayashi et al. [29]. LVH was signiﬁcantly asso-
iated with the occurrence of MACE in our population. In
ddition, Sokolow LVH electrical index was also signiﬁcantly
ssociated with MACE. Silberberg et al. [7] was one of the
rst groups to show that LVH was an independent risk fac-n patients undergoing dialysis, Zoccali et al. reported that
ndexed left ventricular mass was associated with cardio-
ascular events, independent of traditional variables [10].
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owever, this relationship disappeared after adjustment for
eft ventricular systolic function [10], as also observed in our
ultivariable analysis.
Proteinuria has a signiﬁcant impact on the decline of
enal function [34] and an independent role on cardiovas-
ular morbidity and mortality [35—37]. We did not observe
signiﬁcantly higher level of proteinuria in the MACE group.
onversely, blood urea was signiﬁcantly higher in the MACE
roup, whereas there was no signiﬁcant difference in serum
reatinine or estimated glomerular ﬁltration rate between
he two groups. There is a correlation between blood urea
nd protein carbamylation [38], but the impact of carbamy-
ation on cardiovascular mortality is not clearly established.
onetheless, as increased blood urea can be due to dehydra-
ion, we investigated ongoing diuretic treatment and found
hat higher doses of diuretics were being taken at the time of
nclusion in the MACE group. Yet, diuretic treatment was not
ndependently associated with MACE by multivariable anal-
sis. It is likely that the MACE group required more diuretics
o control ﬂuid overload, while the increased blood urea
evel mirrored renal hypoperfusion. This was reﬂected in
he blood urea-to-creatinine ratio, which was higher in the
ACE group than in the MACE-free group.
Finally, combining LVEF and blood urea concentrations
ay help to predict MACE-free survival up to 1 year of
ollow-up. The association of an LVEF > 50% with blood
rea < 15mmol/L was associated in our study with low occur-
ence of MACE (5%) and was observed in 30% of our patients.
he ability of these variables to positively predict MACE
as lower but still useful in this population, with an esti-
ated risk of 20—25% for MACE occurrence, with a positive
redictive value of 67%.
tudy strengths and limitations
he major strength of our study is the enrolment of stable
tage 4 CKD patients, with regular follow-up in consultation,
egardless of cardiovascular status.
The main limitations of our observational study were the
mall size of our cohort and the relatively short follow-up.
onsequently, we were unable to analyse changes in LVH
ver time, or the impact of treatment modiﬁcation. We also
id not measure N-terminal pro-brain natriuretic peptide or
ardiac troponin, which have been shown to be associated
ith cardiovascular mortality [39—41].
onclusion
tage 4 CKD patients have a greatly increased risk of
ACE and premature cardiovascular death. While tradi-
ional risk factors are not associated with MACE in this
peciﬁc population, LVEF and left atrial size were inde-
endent echocardiographic predictors of MACE. Finally, the
ssociation of LVEF > 50% with blood urea < 15mmol/L had a
igh negative predictive value for MACE. In combination with
ncreased blood urea concentrations, which reﬂect renal
ypoperfusion and the kidney’s inability to excrete sodium
hloride, echocardiographic evaluation is probably effective
or identifying at an earlier stage patients who could most
eneﬁt from optimized cardiac management.
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